Results 51 to 60 of about 210,707 (288)

Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial

open access: yes, 2017
PURPOSE To compare the enlargement rate of macular atrophy (ERMA) in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control eyes, as well as analyze risk ...
Sadda, SriniVas R   +6 more
core   +1 more source

Efectividad del bevacizumab intravítreo en régimen bimestral vs treat and extend en el tratamiento del edema macular diabético. [PDF]

open access: yes, 2017
Es un estudio experimental, longitudinal, comparativo, prospectivo y ciego simple en pacientes con edema macular diabético con involucro central para comparar el tratamiento con 2 diferentes regímenes de Antiangiogenico intravítreo (bevacizumab ...
Pérez Salas, José Rubén
core   +1 more source

Adenine base editing to treat progeria syndrome and extend the lifespan

open access: yesThe Journal of Cardiovascular Aging, 2021
Hutchinson-Gilford progeria syndrome (HGPS) is an exceedingly rare and hitherto incurable and fatal disease marked by accelerated aging simultaneously affecting a number of organs. Most cases of HGPS are caused by a single copy of a specific single-nucleotide mutation, c.C1824T, in the LMNA (lamin A) gene.
openaire   +3 more sources

Safety and Effectiveness of a High‐Dose, Tailored Tissue Plasminogen Activator Therapy Protocol: A Joint Pediatric Hematology and Cardiac ICU Quality Improvement Initiative Analysis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric thromboembolism is increasingly encountered in critical care. Systemic thrombolysis with tissue plasminogen activator (tPA) facilitates vessel or valve patency, yet pediatric‐specific protocols remain undefined, and safety concerns persist. Objective To evaluate the efficacy and safety of a tailored, prolonged systemic tPA
Eran Shostak   +5 more
wiley   +1 more source

One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema [PDF]

open access: yes, 2019
PURPOSE: To evaluate real-life outcomes in treatment-naive patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (VEGF) agents using a treat-and-extend regimen without a fixed loading phase.
Zinkernagel, Martin S.   +4 more
core   +1 more source

Global Efforts to Reduce Paediatric Cancer Care Disparities in Radiotherapy: A Decade Change

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background We present an update on the status, needs and challenges faced by paediatric imaging and radiotherapy (RT) programmes globally after a previous survey conducted by the International Atomic Energy Agency (IAEA) 10 years prior. Methods We developed and distributed a 121‐question survey to radiation oncologists, medical physicists and ...
Raymond B. Mailhot Vega   +10 more
wiley   +1 more source

Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study

open access: yes, 2023
 Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study 
Yusuke Arai (16036109)
core   +1 more source

Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial

open access: yes, 2018
BACKGROUND AND OBJECTIVE: Compare fixed monthly dosing of ranibizumab to treat-and-extend (T&E) ranibizumab during a period of 24 months for diabetic macular edema (DME) treatment.
Hershel R. Patel   +7 more
core   +2 more sources

Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice

open access: yesOphthalmology and Therapy, 2019
Introduction Treat-and-extend (T&E) and pro re nata (PRN; ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the ...
Beverley A. Curry   +4 more
doaj   +1 more source

Survival After Hematopoietic Stem Cell Transplantation in Diamond–Blackfan Anemia Syndrome: The Role of Iron Overload—A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT We assessed the effect of iron overload (IO) on mortality and complications following hematopoietic stem cell transplantation (HSCT) in patients with Diamond–Blackfan anemia syndrome (DBAS) in a systematic review of individual participant data and cohort data from observational studies.
Geoffrey Z. L. Kuppens   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy